Showing results (11-20 of 27) with videos related to
Sort By:
Pageof 3
Pathology Oncology Research : POR|October 8, 2003
Brain-metastatic melanoma: a neurotrophic perspectiveDario Marchetti, Yvonne Denkins, Jane Reiland, et al.Journal of Pharmacological and Toxicological Methods|May 22, 2013
Preclinical QT safety assessment: cross-species comparisons and human translation from an industry consortiumHenry Holzgrefe, Georg Ferber, Pascal Champeroux, et al.Journal of Veterinary Internal Medicine|September 8, 2006
Association of Helicobacter with cholangiohepatitis in catsAndrea Greiter-Wilke, E Scanziani, S Soldati, et al.Journal of Veterinary Internal Medicine|February 18, 2005
Quantitative analysis of inflammatory and immune responses in dogs with gastritis and their relationship to Helicobacter spp. infectionBo Wiinberg, Anette Spohr, Hans Henrik Dietz, et al.Journal of Pharmacological and Toxicological Methods|February 2, 2015
Renal studies in safety pharmacology and toxicology: A survey conducted in the top 15 pharmaceutical companiesAmanda Benjamin, David J Gallacher, Andrea Greiter-Wilke, et al.Journal of Pharmacological and Toxicological Methods|May 29, 2016
Human ex-vivo action potential model for pro-arrhythmia risk assessmentGuy Page, Phachareeya Ratchada, Yannick Miron, et al.Journal of Pharmacological and Toxicological Methods|March 30, 2023
Improving the in Vivo QTc assay: The value of implementing best practices to support an integrated nonclinical-clinical QTc risk assessment and TQT substituteHugo M Vargas, Eric I Rossman, Todd A Wisialowski, et al.Journal of Pharmacological and Toxicological Methods|August 12, 2017
The Safety Pharmacology Society salary surveyMichael K Pugsley, Simon Authier, Tiffini Brabham, et al.Journal of Pharmacological and Toxicological Methods|July 17, 2024
Assessment of corrected JT-peak (JTpc) and Tpeak-to-Tend (TpTec) as proarrhythmia biomarkers in non-human primates: Outcome from a HESI consortiumEmmanuel Boulay, Simon Authier, Theresa Bartko, et al.Molecular Psychiatry|February 4, 2026
Novel selective morpholine trace amine-associated receptor 1 partial agonists show promising preclinical effects for neuropsychiatric disorders and are well tolerated in healthy volunteersCéline Fournier, Danièle Buchy, Susanne Mohr, et al.Pageof 3